Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

CompletedOBSERVATIONAL
Enrollment

242

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions
Hemophilia AHemophilia B
Interventions
OTHER

Non-treatment, seroprevalence

Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)

Trial Locations (23)

1090

AKH - Medizinische Universität Wien, Vienna

10249

Vivantes Klinikum im Friedrichshain, Berlin

13385

Hôpital de la Timone, Marseille

20122

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan

28046

Hospital Universitario La Paz, Madrid

29010

Hospital Regional Universitario de Malaga, Málaga

29425

Medical University of South Carolina (MUSC), Charleston

29609

Hôpital Morvan, Brest

31033

Presidio Ospedaliero di Castelfranco Veneto, Castelfranco Veneto

36100

Ospedale San Bortolo di Vicenza, Vicenza

37007

Hospital Universitario de Salamanca, Salamanca

44093

CHU de Nantes Site Hotel Dieu, Nantes

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48824

Michigan State University, East Lansing

50134

Azienda Ospedaliera Universitaria Careggi, Florence

59037

Hopital Jeanne de Flandre - CHU Lille, Lille

60590

Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt

69677

Groupement Hospitalier Est- Hôpital Louis Pradel, Bron

77030

Gulf States Hemophilia and Thrombophilia Center, Houston

80045

University of Colorado Hemophilia & Thrombosis Center, Aurora

90007

Orthopaedic Hemophilia Treatment Center, Los Angeles

94275

Groupement Hospitalier Sud - Hôpital Bicêtre, Le Kremlin-Bicêtre

98104

University of Washington, Seattle

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT03185897 - Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia | Biotech Hunter | Biotech Hunter